Literature DB >> 4146641

Further studies on the mechanism of antipsychotic action: potentiation by alpha-methyltyrosine of thioridazine effects in chronic schizophrenics.

A Carlsson, B E Roos, J Wålinder, A Skott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4146641     DOI： 10.1007/bf01244665

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


× No keyword cloud information.
  9 in total

1.  A simple and reliable subclassification of chronic schizophrenia.

Authors:  J K WING
Journal:  J Ment Sci       Date:  1961-09

2.  The measurement of behaviour in chronic schizophrenia.

Authors:  J K Wing
Journal:  Acta Psychiatr Scand       Date:  1960       Impact factor: 6.392

3.  Potentiation of phenothiazines by -methyltyrosine in treatment of chronic schizophrenia.

Authors:  A Carlsson; T Persson; B E Roos; J Wålinder
Journal:  J Neural Transm       Date:  1972       Impact factor: 3.575

4.  Gas chromatographic identification of thioridazine in plasma, and a method for routine assay of the drug.

Authors:  S H Curry; G P Mould
Journal:  J Pharm Pharmacol       Date:  1969-10       Impact factor: 3.765

5.  Behavioral effects of haloperidol after tyrosine hydroxylase inhibition.

Authors:  S Ahlenius; J Engel
Journal:  Eur J Pharmacol       Date:  1971-07       Impact factor: 4.432

6.  Serum levels of thioridazine in psychiatric patients and healthy volunteers.

Authors:  E Mårtensson; B E Roos
Journal:  Eur J Clin Pharmacol       Date:  1973-10       Impact factor: 2.953

7.  5-Hydroxyindolacetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis.

Authors:  R Sjöström; B E Roos
Journal:  Eur J Clin Pharmacol       Date:  1972-06       Impact factor: 2.953

8.  Catecholamine-drug interactions in man.

Authors:  A Sjoerdsma
Journal:  Pharmacol Rev       Date:  1966-03       Impact factor: 25.468

9.  Alpha-methyl-p-tyrosine (AMT) in schizophrenia.

Authors:  S Gershon; L J Hekimian; A Floyd; L E Hollister
Journal:  Psychopharmacologia       Date:  1967
  9 in total
  7 in total

1.  Potentiation by lithium of the haloperidol-induced behavioural suppression.

Authors:  S Ahlenius; J Engel
Journal:  J Neural Transm       Date:  1974       Impact factor: 3.575

2.  Normalization by antipsychotic drugs of biochemically induced abnormal behavior in rats.

Authors:  S Ahlenius; J Engel
Journal:  Psychopharmacology (Berl)       Date:  1976-08-26       Impact factor: 4.530

3.  Antipsychotic treatment with alpha-methyltyrosine in combination with thioridazine: prolactin response and interaction with dopaminergic precursor pools.

Authors:  M Larsson; R Ohman; L Wallin; J Wålinder; A Carlsson
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

4.  Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.

Authors:  A Wolkin; E Duncan; M Sanfilipo; S Wieland; T B Cooper; J Rotrosen
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 5.  alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

6.  RMI-81,582, a novel antipsychotic drug.

Authors:  M A Young; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1980-01       Impact factor: 4.530

Review 7.  Glutamate and dopamine in schizophrenia: an update for the 21st century.

Authors:  Oliver Howes; Rob McCutcheon; James Stone
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.